PE-22-28: A Tracking Guide for a Research-Stage Antidepressant Peptide

PE-22-28 is a synthetic analog of spadin, a peptide fragment that blocks the TREK-1 potassium channel. TREK-1 is interesting because mice lacking it show an antidepressant-resistant-to-depression phenotype, and blocking it produces antidepressant-like effects in animal models faster than classic SSRIs. PE-22-28 was engineered to be a more stable, more usable spadin.

The headline you should hold onto: this is research-stage. It is not an approved antidepressant anywhere, and the human data is essentially absent.

What it is claimed to do

• Produce rapid antidepressant-like effects via TREK-1 blockade
• Promote hippocampal neurogenesis in animal models
• Avoid some side effects associated with SSRIs (animal data)

The honest evidence picture

• Promising rodent studies, no controlled human efficacy or safety trials
• The "faster than SSRIs" framing comes from animal behavioural tests, not human depression scores
• Dose, route, and cycle for humans are unestablished

Typical protocol shape (as reported)

• Subcutaneous or intranasal administration in self-experimenter logs
• Small doses, often daily or every-other-day
• Short experimental runs

What to track daily

• Dose, route, time
• Mood (0-10) and a short standardised scale if your clinician suggests one
• Anxiety and rumination
• Sleep onset and quality
• Appetite and energy
• Any agitation, which is worth flagging early with any antidepressant-type agent

What to track weekly

• A validated mood questionnaire score for an objective trend
• Social engagement and activity level (often more telling than self-rated mood)
• Side-effect tally

Realistic expectations

• Depression and anxiety respond strongly to placebo and to the act of self-monitoring itself
• Without controlled human data, you cannot know whether an effect is the peptide
• Mood compounds are exactly where careful baselines and slow conclusions matter most

Common mistakes

• Stopping a prescribed antidepressant to try this - a genuinely dangerous move that needs a doctor
• Treating animal speed-of-onset claims as a human promise
• No validated mood measure, so the log is all narrative
• Ignoring early agitation or sleep disruption

A tracking template

• Week 0: baseline mood scale and daily logs, no compound
• Weeks 1-4: protocol, daily logs plus weekly validated scale
• Weeks 5-6: washout with continued logging

Safety notes

This is an unapproved research compound with no human safety profile. Anyone with diagnosed depression should be working with a clinician, and should never swap a prescribed treatment for an experimental peptide. Mood changes, including worsening or agitation, must be taken seriously and reviewed with a doctor promptly.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.